✨ Free AI Report
Stoke Therapeutics, Inc.: Key Facts, Business Model & Financial Analysis Read the overview below or get the full interactive report with Cyborg Score, analyst debate audio & saved-company playlists — free, no credit card.
Get Free Report →
Home Company Research Stoke Therapeutics, Inc.
Company Research

Stoke Therapeutics, Inc.: Business Overview, Financials & Competitive Analysis

Stoke Therapeutics, Inc. scores 7/10 on the AskCyborg Cyborg Score (Strong). RNA medicine platform targeting rare genetic diseases with lead asset advancing toward regulatory approval and strong balance sheet supporting multi-year runway. Analyst consensus rates STOK as "Strong Buy." 2024 revenue surged 316% to $36.56 million while losses decreased to $88.98 million. The company held $391.7 million in cash as.

What is Stoke Therapeutics, Inc.'s industry? Stoke Therapeutics, Inc. (stoketherapeutics.com) operates in Biopharmaceuticals - RNA Therapeutics & Rare Genetic Diseases. AskCyborg classifies Stoke Therapeutics, Inc. under Biopharmaceuticals - RNA Therapeutics & Rare Genetic Diseases in its company registry.

Stoke Therapeutics is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, using its proprietary TANGO (Targeted Augmenta...

7/ 10Strong

Cyborg Score thesis

RNA medicine platform targeting rare genetic diseases with lead asset advancing toward regulatory approval and strong balance...

Read the full analyst-debate transcript →
Industry Biopharmaceuticals - RNA Therapeutics & Rare Genetic Diseases
3 named competitors
3 recent developments
11 analyst dimensions
Synthesized from analyst-debate stress-testing across 11 dimensions and hundreds of data points. Methodology →
Cyborg Score recalibrated: October 19, 2026
AI-Generated Research
30+ Page Report

Get the Latest Stoke Therapeutics, Inc. Report

Up-to-date AI-powered research, analyst debate audio & saved-company playlists

Get Current Report Free
✓ No credit card required
or get it by email

Analyst-debate audio for Stoke Therapeutics, Inc.

AskCyborg analysts argue the bull and bear cases for Stoke Therapeutics, Inc. across 11 stress-tested dimensions. Listen on your commute -- faster than reading the 30-page report.

Play the free intro →
Free intro · Pro unlocks the full analyst debate
What's in This Report
Stoke Therapeutics, Inc. OverviewStrategic ProfileCompetitive LandscapeIndustry ContextKey facts
Get Interactive Report Freeor start reading below

Stoke Therapeutics, Inc. Overview

Pro stress-test →

Stoke Therapeutics is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, using its proprietary TANGO (Targeted Augmentation of Nuclear Gene Output) approach to develop antisense oligonucleotides (ASOs) to selectively restore protein levels. The company's first compound, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe and progressive genetic epilepsy.

Strategic Profile

Pro stress-test →

Stoke has obtained regulatory designations for zorevunersen including orphan drug, rare pediatric disease, and Breakthrough Therapy Designation, and maintains a strategic collaboration with Biogen under which the companies jointly advance zorevunersen for Dravet syndrome with defined regional commercialization rights. The company is pursuing treatment for autosomal dominant optic atrophy (ADOA), the most common inherited optic nerve disorder.

Competitive Landscape

Pro stress-test →

Stoke operates in the RNA therapeutics space targeting rare genetic diseases where few treatment options exist. Competitors include other antisense and gene therapy platforms, but Stoke's differentiated TANGO approach targeting haploinsufficiency diseases provides competitive positioning in underserved neurological and ophthalmic markets.

Industry Context

Stoke Therapeutics, Inc. operates in Biopharmaceuticals - RNA Therapeutics & Rare Genetic Diseases.

Key facts

Founded: 2014 · Headquarters: Bedford, Massachusetts, United States · Revenue: $36.56M (2024)

What the AI analysts debated

AI-generated and not independently verified: selected findings from the multi-agent debate on Stoke Therapeutics, Inc..

  • Phase 3 EMPEROR study enrollment expected to complete Q2 2026, with topline data planned for mid-2027 and rolling NDA initiation targeted in first half of 2027.
  • Phase 1 OSPREY study of STK-002 for ADOA launched with first patient dosed in early 2026.
+2 more AI-generated counter-arguments unlock with Pro. Read the full analyst debate →

Recent developments

Material events tracked by the AskCyborg corpus.

  • February 2026Phase 1 OSPREY study of STK-002 for ADOA launched with first patient dosed
  • February 2026Signed long-term lease for 98,500 sq ft headquarters in Waltham, MA
  • +1 moreTrack every material event for Stoke Therapeutics, Inc. as it happens. Explore monitoring →
Get alerted when Stoke Therapeutics, Inc. has a new material development →

Named competitors

Pulled from the analyst-debate framework. Click any competitor to see their Cyborg Score.

Antisense Oligonucleotides (ASOs)Co-developing zorevunersen for Dravet syndrome→Gene Therapy PlatformsAlternative approaches to genetic disease treatment→RNA TherapeuticsCompeting RNA-based medicine platforms→

Compare Stoke Therapeutics, Inc. with another company

Pick any company in the AskCyborg corpus to see side-by-side Cyborg Scores and insights.

vs
Side-by-side opens in your AskCyborg account

Industry context

Stoke Therapeutics, Inc. operates in Biopharmaceuticals - RNA Therapeutics & Rare Genetic Diseases. See how the rest of the sector scores on the Cyborg framework.

Browse Biopharmaceuticals - RNA Therapeutics & Rare Genetic Diseases research →
NEW · MCP server

Ask your AI assistant about Stoke Therapeutics, Inc.

Install the free AskCyborg MCP server in Claude, Cursor, Cline, Continue, or Windsurf and ask any of these in-line:

“Compare Stoke Therapeutics, Inc. and its top competitor on Cyborg Score”
“What did Stoke Therapeutics, Inc. do this quarter?”
“Is Stoke Therapeutics, Inc. a defensible business in 5 years?”
Install the MCP server (10 sec) →
Free, anonymous, no API key required

How AskCyborg research is made

⚔

AI analyst debate, not single-author opinion

Every report is generated by a panel of AI analysts arguing across 11 dimensions, so counter-arguments sit alongside the case. The debate is a reasoning process; it does not independently verify facts.

📊

Dated, not live

The Cyborg Score and recent developments reflect public sources as of the date shown and can miss or lag recent events. Check primary sources before relying on them.

🔗

Methodology open at /methodology

The framework, dimensions, and band breakdowns are documented. The Cyborg Score is an AI-generated opinion under that framework, not a credit rating or an investment recommendation.

🔒

Free tier is free

No credit card to read the research. Pro adds saved-company audio playlists, monitoring, audio briefings on demand, and PDF export for $39/mo annual.

Sources: public filings, regulatory data, and news flow, analysed by AI models. Read the methodology →

AI-generated research summary based on public sources; it may contain errors or omissions. Not investment advice. Not reviewed or endorsed by the companies covered. Report an error: legal@askcyborg.com · Terms of Service

Frequently asked questions

What does Stoke Therapeutics, Inc. do?+
Stoke Therapeutics is a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, using its proprietary TANGO (Targeted Augmenta...
What is Stoke Therapeutics, Inc.'s Cyborg Score?+
Stoke Therapeutics, Inc. has a Cyborg Score of 7/10 (Strong). The score synthesizes business model, financials, leadership, competitive position, technology, marketing, and ESG dimensions across hundreds of data points.
Who are Stoke Therapeutics, Inc.'s main competitors?+
Named competitors include Antisense Oligonucleotides (ASOs), Gene Therapy Platforms, RNA Therapeutics. The full competitive landscape is in the AskCyborg report.
How can I get the full Stoke Therapeutics, Inc. research report?+
Get the report plus analyst-debate audio at askcyborg.com -- no credit card required for preview access. Pro adds saved-company audio playlists and monitoring.
How current is the Stoke Therapeutics, Inc. research?+
The Cyborg Score is recalibrated weekly. Recent developments are tracked continuously and surfaced in every report.

Track Stoke Therapeutics, Inc. over time

Pro members get saved-company audio playlists, Cyborg Score recalibrations, and monitoring for material events across the AskCyborg corpus.

See Pro features
From $39/mo annual

Top-scored companies on AskCyborg

The strongest performers across the analyst-debate framework.

9Advantest Corporation9Anthropic9Apple Inc.9Applied Materials, Inc.9Arista Networks9Aritzia Inc.9ASML Holding N.V.9BAE Systems plc9Barrick Mining Corporation9Berkshire Hathaway Inc.